Helixmith's 'Ngenesis' Obtains Industrial Technology Verification Certificate

[Asia Economy Reporter Lee Chun-hee] Helixmith announced on the 24th that it has obtained the ‘Industrial Technology Confirmation Certificate’ from the Ministry of Trade, Industry and Energy for its gene therapy drug under development, ‘Engensis (VM202)’.

The Industrial Technology Confirmation System is a system that verifies whether the technology possessed by companies, etc., qualifies as industrial technology in response to the advancement and increasing complexity and diversity of industrial technology. When an Industrial Technology Confirmation Certificate is obtained, it provides legal grounds to respond quickly in case the relevant industrial technology is infringed or leaked. Accordingly, Engensis was recognized as a ‘gene therapy drug optimized for the expression of hepatocyte growth factor (HGF) with neuroregeneration and angiogenesis efficacy’.

Engensis is a drug composed of plasmid DNA that expresses the HGF protein. Through previous research and clinical trials, it is explained that a simple muscle injection can produce HGF protein in the body, resulting in effects such as nerve regeneration, blood vessel formation, and prevention of muscle atrophy.

Yoo Seung-shin, CEO of Helixmith, said, “Following the ‘Advanced Technology and Product Confirmation Certificate’ obtained last January, we have been recognized for the technology of Engensis with this ‘Industrial Technology Confirmation Certificate.’ We will continue to invest and make efforts in technology to leap forward as a global gene therapy company representing South Korea in the world market.”

This content was produced with the assistance of AI translation services.